Interventional × Recurrence × Vorinostat × Clear all
NCT00994500 2013-07-02

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
20 enrolled